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Abstract
A sensitive and rapid routine LC method was validated for measuring cefotaxime incorpo-
rated in three different pH-sensitive nanoparticles. The drug was chromatographed on a C18
reversed-phase column; the mobile phase used was 0.05 M aqueous ammonium acetate,
acetonitrile and tetrahydrofuran (87:11:2, v/v) adjusted to pH 5.5 with acetic acid. The flow
rate was 1 mL min-1 and cefotaxime was quantified at 254 nm, with a sensitivity range of
0.005 AUFS. The validated method was specific, linear (R2  0.999), precise and accurate
in a concentration range of 0.2–50.0 lg mL-1. The method was rapid, selective and suitable
for evaluation of cefotaxime in pH-sensitive Eudragit nanoparticles.
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Introduction
Cefotaxime sodium is a water soluble semi-
synthetic third-generation cephalosporin
(Fig. 1). It is a peptidomimetic drug which
exists as zwitterionic compound at physio-
logical pH and unable to permeate the gas-
trointestinal mucosa. Thus, it is not
appreciably absorbed on peroral adminis-
tration and consequently presents poor oral
bioavailability, falling into theclass IIIof the
Biopharmaceutics Classification System [1].
Due to the cefotaxime sodium similar-
ity in structure and biopharmaceutical
profile with proteins and peptides it might
be used as a model drug for characterizing
the incorporation of peptidomimetics in
nanocarriers. This is important since the
majority of the newly developed thera-
peutic molecules are peptides or proteins
[2, 3]. Nanocarriers, such as pH-sensitive
nanoparticles, may constitute an alterna-
tive to overcome the difficulties related to
poor permeability of peptidomimetic
compounds and improve their oral bio-
availability. This approach has been ap-
plied to different drugs [4–7].
pH-Sensitive nanoparticles are ma-
trix-type disperse systems of nanometer
size [8]. They can protect labile macro-
molecules from stomach acid and the
first-pass metabolism in the gastrointes-
tinal tract [9] and reduce side effects [10].
Moreover, due to their inherent pH-
sensitive property, the incorporated drug
can be released at a specific pH within
the gastrointestinal tract, as close as
possible to its absorption window [7, 11].
Acrylic polymers such as Eudragit L100,
Eudragit L100-55 and Eudragit S100 are
co-polymers of poly(methacrylic acid
and methacrylate), which can dissolve
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rapidly at specific pH values. Thereby,
the release properties of nanoparticles
formed by these polymers exhibit sig-
nificant pH-sensitivity [7].
In order to test the usefulness of
Eudragit pH-sensitive nanoparticles as
potential carriers to improve cefotaxime
sodium oral bioavailability, we are car-
rying out in vivo studies for formulations
prepared with different types of Eudra-
git. To facilitate the pharmaceutical
development of cefotaxime sodium-con-
taining nanoparticle formulations an
analytical method for the quantitation of
drug and characterization of its in vitro
release profile is needed to guarantee the
reliability of the results [12, 13]. Different
methods for determination of cefotaxime
sodium in simple solutions and plasma
have been described [1, 14–22]. However,
some important drawbacks, such as
complex sample preparation and/or
incomplete validation, were observed for
the reported methods. As such, new
methodologies have been developed to
overcome these limitations when a plas-
ma matrix is used [23–25]. The aim of the
present work was to adapt this method
for the quantitation of cefotaxime which
was entrapped for the first time into pH-
sensitive nanoparticles and to validate it
through the methodologies and param-
eters recommended by the International
Conference on Harmonization [26, 27],
which are similar to the ones established
by the United States Pharmacopoeia 29
(USP 29) [28].
Experimental
Chemicals and Reagents
Cefotaxime sodium was obtained from
Orchid Chemicals and Pharmaceuti-
cals (Chennai, India). Eudragit L100,
Eudragit L100-55 and Eudragit S100
were purchased from Degussa (Singa-
pore). Disodium hydrogen orthophos-
phate was obtained from Fisher
Scientific (Singapore). Acetonitrile was
acquired from LAB-SCAN (Bangkok,
Thailand). Ammonium acetate, per-
chloric acid (70%, w/w) and tetrahy-
drofuran were obtained from Merck
(Darmstadt, Germany). Glacial acetic
and hydrochloric acid were purchased
from BDH (Poole, England). Sodium
chloride was acquired from Fluka
(Deisenhofen, Germany). Pepsin, pan-
creatin and monobasic potassium phos-
phate were purchased from Sigma (St.
Louis, MO, USA). LC grade water was
obtained by a MilliQ system (Millipore,
Singapore). All solvents and chemicals
used were of analytical or LC grade.
Apparatus
The experiments were performed on an
Waters Breeze LC system (Waters, Mil-
ford, MA, USA), comprising a Waters
1525 Binary LC pump, a 717 Plus
autosampler, a Rheodyne 7725i sample
injector, a Symmetry C18 (5 lm,
4.6 9 250 mm) column, fitted with a
Universal Sentry Guard Holder packed
with Nova-Pack cartridge, a 2487 dual
wavelength absorbance detector and a
computer with a Breeze software that
controls the system and displays the re-
sults. The pH of the solutions was mea-
sured by a pH-meter from Mettler
Toledo Seven Easy (Mettler Toledo,
Shah Alam, Malaysia).
Chromatographic Conditions
The mobile phase was composed of
a mixture of 0.05 M aqueous ammo-
nium acetate–acetonitrile–tetrahydrofuran
(87:11:2, v/v), adjusted to pH 5.5 with
glacial acetic acid. The mobile phase was
filtered using a 0.45 lm Teflon mem-
brane filter (Millipore, Milford, MA,
USA) and degassed by sonication prior
to use. It was pumped through the sys-
tem at a flow rate of 1.0 mL min-1 by
isocratic elution. All the determinations
were performed at ambient temperature.
The detection wavelength was set at
254 nm and the sensitivity adjusted to
0.005 absorbance units full scale
(AUFS). The samples were quantified
based on the peak height.
Nanoparticle Preparation
and Characterization
pH-Sensitive nanoparticles were pre-
pared by a novel pH-sensitive nanopre-
cipitation method, which is under
optimization [11]. Briefly, a 0.7% poly-
meric solution (Eudragit L100, Eudragit
L100-55 or Eudragit S100) was added
with an amount of cefotaxime sodium to
obtain a 1:1 (w/w) polymer:drug ratio.
Then, a precipitating solution (1 M ace-
tic acid) was added under moderate
stirring. Obtained nanodispersions were
left at room temperature for established
periods of time. Non-incorporated drug
was separated by ultracentrifugation at
90,0009g for 4 h (Optima LE 80-K
ultracentrifuge, Beckman Coulter, Ful-
lerton, CA, USA). Pelleted nanoparticles
were quickly frozen by immersion into
liquid nitrogen and freeze-dried without
heating for 24 h (Labconco Freeze Dry
System, Kansas, MI, USA). Blank
nanoparticles were prepared by the same
method but omitting the addition of
drug.
Size and zeta potential of nanoparticles
were measured using a Zetasizer Nano ZS
(Malvern instruments, Malvern, UK).
Calculation of the percentage of
nanoparticle recovery, drug encapsulation
efficiency and drug entrapment was per-
formed using the following equations [29]:
Nanoparticle recovery %ð Þ
¼ Mass of nanoparticle recovered
Mass of polymeric material and drug used
 100
Drug content %ð Þ
¼ Mass of drug in nanoparticles
Mass of nanoparticles recovered
 100
Drug entrapment %ð Þ
¼ Mass of drug in nanoparticles
Mass of drug used in the formulation
 100
Preparation of Standard
Solutions
A cefotaxime sodium stock solution
(50 lg mL-1) was freshly prepared by
Fig. 1. Chemical structure of cefotaxime
sodium
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dissolving the drug in 0.04 M NaH2-
PO42H2O buffer solution (pH 5.5). The
standard solutions were obtained by se-
rial dilutions of the stock solution with
the same buffer to give different con-
centrations over the range of interest
(0.2–50 lg mL-1). Upon preparation all
solutions were covered with aluminum
foil in order to protect them from light.
Preparation of Sample
Solutions for Cefotaxime
Sodium Quantitation in
Nanoparticles
Sample solutions were prepared by dis-
solving 150 mg of freeze-dried cefotax-
ime sodium loaded nanoparticles in
0.04 M NaH2PO42H2O buffer solution
(pH 7, adjusted with glacial acetic acid)
under sonication. This pH was selected
in order to achieve a complete dissolu-
tion of the used polymers, since the
maximum pH thresholds are 5.5 for
Eudragit L100-55, 6.0 for Eudragit L100
and 7.0 for Eudragit S100 [30]. A 250 lL
aliquot of the previous solution was
further diluted to 25 mL with the same
phosphate buffer but with a pH of 5.5
(adjusted with glacial acetic acid), which
corresponds to the maximum cefotaxime
sodium stability. Then, samples were
subjected to LC analysis. All analyses
were performed in quadriplicate.
Statistical Analysis
Analysis of variance (ANOVA) was used
to validate statistically the differences
among the entrapment values of cefo-
taxime sodium in nanoparticles. Analy-
sis was performed using SPSS 12 (SPSS,
Chicago, IL, USA).
Method Validation
The procedures and parameters adopted
for the validation of the chromato-
graphic method in this study are those
described in the ICH guidelines [26, 27],
which are similar to the ones established
by the USP 29 [28]. The following
parameters were determined: specificity,
Fig. 2. Representative chromatograms obtained following injection of a cefotaxime standard
solution (3.13 lg mL-1), b cefotaxime standard solution (0.78 lg mL-1) spiked with Eudragit
L100 nanoparticles, c cefotaxime standard solution (1.56 lg mL-1) spiked with Eudragit L100-
55 nanoparticles and d cefotaxime standard solution (3.13 lg mL-1) spiked with Eudragit S100
nanoparticles
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range and linearity, precision, accuracy,
DL, QL, robustness and system suit-
ability test.
Specificity
ICH defines specificity as the ability to
assess unequivocally the analyte in the
presence of components that may be
expected to be present, such as impuri-
ties, degradation products and matrix
components. In practice, this can be
performed by spiking the drug substance
with appropriate levels of impurities/ex-
cipients and demonstrating that the as-
say results are unaffected by the presence
of these potential interferences [26, 27].
In the present study, the specificity of the
analytical method was determined by
comparing the results from the analysis
of cefotaxime standard solutions over
the range of interest (0.2–50 lg mL-1)
and the same standards spiked with
blank nanoparticles prepared with each
type of Eudragit.
Linearity and Range
The linearity of an analytical method is
its ability to produce test results that are
directly proportional to the concentra-
tion of analyte in the sample, within a
given range [27]. In the present study,
linear regression was performed by
plotting average peak height (y) versus
the analyte concentration (x) in the
concentration range of 0.2–50 lg mL-1.
Calibration curves were constructed at
nine concentration levels using the lin-
ear-squares regression procedure. The
overall experiments were repeated six
times on different days. The obtained
peak height values were averaged at each
concentration.
Accuracy
The accuracy of an analytical method
expresses the closeness of agreement be-
tween the value that is accepted either as
a conventional true value (or an accepted
reference value) and the achieved exper-
imental value [27]. Accuracy is normally
calculated as the percentage of recovery
by the assay of known spiked amounts
of analyte into the sample. In the present
study, to assess the accuracy of the
proposed method, recovery experiments
were carried out by spiking known
amounts of cefotaxime sodium to blank
nanoparticles (L100, L100-55 and S100)
to achieve final theoretical concentra-
tions of cefotaxime sodium between 0.2
and 50 lg mL-1. Experiments were done
at nine concentration levels. For each
level, drug content was determined in
replicates (n = 6).
Precision
The precision of an analytical method is
the degree of agreement among individ-
ual test results when the method is ap-
plied repeatedly to multiple samplings of
a homogeneous sample [27]. It is nor-
mally expressed as the coefficient of
variation in percentage (CV) for a sig-
nificant number of samples. Precision
may be measured as repeatability,
reproducibility and intermediate preci-
sion. Since reproducibility refers to the
use of analytical procedure in different
laboratories, for this specific case we
have studied repeatability (intra-assay
precision) and intermediate precision. To
determine intra-assay precision six rep-
licates of standard solutions (nine dif-
ferent concentrations) were analyzed by
the same analyst within the same day.
Intermediate precision of the assay was
determined by analysis of the same
standard solutions on six consecutive
days by the same analyst.
Detection Limit and Quantitation Limit
The detection limit (DL) is defined as the
lowest concentration of the analyte in a
sample that can be detected by the
method of analysis [27]. The quantita-
tion limit (QL) is defined as the lowest
concentration of the analyte in sample
that can be determined with acceptable
precision and accuracy under stated
operational conditions for the method.
In the present work, DL and QL were
calculated according to the referred ICH
guideline, from the slope and the standard
deviation of the y-intercept of the mean of
six calibration curves, as it follows:
DL ¼ 3:3r
S
QL ¼ 10r
S
where r is the standard deviation of
y-intercepts of regression lines and S is
the slope of the calibration curves.
Robustness
The evaluation of robustness should be
considered in order to ensure that the
validity of the analytical procedure is
maintained whenever used, even for
small variations on analytical solutions
[26, 27]. In this study, robustness was
evaluated as the percentage of recovery
by the assay when deliberate variations
of pH or media composition on cefo-
taxime solutions were performed. This
approach can predict the method appli-
cability to pH variations/media compo-
sition during sample handling and in
vitro testing.
Recovery experiments were carried
out by measuring cefotaxime sodium on
standard solutions (125 lg mL-1) pre-
pared at different pH values (1.0; 4.0;
4.3; 4.6; 5.0 and 7.0) and on USP 29
simulated gastric and intestinal fluids.
Experiments were done in replicates
(n = 4). Buffer solution pH 1.0 ± 0.1
consisted in 0.1 M HCl. All the other
buffer solutions (pH 4.0 ± 0.1,
4.3 ± 0.1, 4.6 ± 0.1, 5.0 ± 0.1 and
7.0 ± 0.1) were composed by 0.05 M
NaH2PO42H2O and the respective pH
values were adjusted with glacial acetic
acid. Upon preparation, the cefotaxime
Table 1. Summary of standard curve results
Concentration
of cefotaxime
(lg mL-1)
Average
peak height
(V)
CV
(%)
0.20 538 1.48
0.39 1,102 1.91
0.78 2,102 0.50
1.56 3,868 1.35
3.13 7,995 1.08
6.25 15,937 0.91
12.50 31,841 1.02
25.00 63,947 0.49
50.00 127,973 0.61
y-Intercept = 0.63201 ± 79.86 and Slope =
2,555.92 ± 2.04, with confidence limits P =
0.05; correlation coefficient (r) = 0.99998;
coefficient of determination (R2) = 0.99997
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sodium standard solutions were incu-
bated at 37 C in a dissolution tester
vessel (Vankel VK 7000 dissolution tes-
ter, Vankel, Cary, NC, USA) with the
paddle speed rotating at 100 rpm. At
pre-established times 1 mL samples were
collected and replaced by fresh medium.
Aliquots were further diluted with 9 mL
of 0.5 M ammonium acetate buffer
solution and a mixture with pH of 5.5
was obtained. The amount of cefotaxime
in the samples was immediately analyzed
after collection by the proposed LC
method.
Results and Discussion
Specificity
Figure 2a shows a representative chro-
matogram of a cefotaxime sodium
standard solution (3.13 lg mL-1) with
a retention time of 6.3 min. Figure 2b–d
show representative chromatograms
obtained for cefotaxime sodium stan-
dard solutions of different concentra-
tions (0.78; 1.56 and 3.13 lg mL-1)
spiked with a fixed amount of blank
nanoparticles ($0.375 mg of nanopar-
ticles mL-1 in the final solution) pre-
pared with each one of the three
Eudragit polymers (L100, L100-55 and
S100). The total running time for the
samples was 10 min. No peak from
possible degradation products was ob-
served in the chromatograms, as men-
tioned in other studies [31], showing the
purity and stability of cefotaxime so-
dium in the studied conditions. The
absence of any peak or interference at
the elution point of cefotaxime rendered
the method specific.
Linearity and Range
Regression statistics are summarized in
Table 1. The assay was linear with a CV
of 4.1% in the response factors (peak
height divided by concentration) in the
tested concentration range and coeffi-
cients of correlation (r) and determina-
tion (R2) were found to be higher than
0.9999, indicating a functional linear
relationship (over 99.99%) between the
concentration of cefotaxime sodium in
buffer solutions and the peak height.
Results demonstrate good linearity in
the studied range, meeting the criteria
proposed by Epshtein [32].
Accuracy
Table 2 summarizes the accuracy results,
expressed as percent recovery and CV.
Recovery values were within the ranges
of 98.3–101.0% (CV = 1.0–3.2), 98.2–
100.7% (CV = 1.0–3.2) and 98.8–
102.3% (CV = 1.0–2.8) for Eudragit
L100, Eudragit L100-55 and Eudragit
S100 nanoparticles, respectively. Overall
mean recovery values were 100.0%
(n = 54) for Eudragit L100 nanoparti-
cles, 99.6% (n = 54) for Eudragit L100-
55 nanoparticles and 100.2% (n = 54)
for Eudragit S100 nanoparticles. Be-
cause the mean recovery results were
within an acceptable ±3% range (1.84–
1.93%), according to Segall et al. [33] the
method was deemed accurate.
Table 2. Recovery of cefotaxime from nanoparticle formulations prepared with different
Eudragit types
Theoretical cefotaxime
concentration (lg mL-1)
Eudragit L100
nanoparticlesa
Eudragit L100-
55 nanoparticlesa
Eudragit S100
nanoparticlesa
Recovery
(%)
CV
(%)
Recovery
(%)
CV
(%)
Recovery
(%)
CV
(%)
0.20 98.3 1.1 100.7 2.7 99.0 2.4
0.39 99.5 2.0 100.4 2.0 98.8 1.3
0.78 101.0 2.7 100.3 1.5 101.9 1.8
1.56 100.9 1.5 99.6 1.1 100.3 1.2
3.13 99.4 1.0 99.5 1.0 102.3 2.5
6.25 99.6 3.2 99.0 1.2 100.2 2.8
12.5 101.3 1.7 98.2 1.7 99.8 1.0
25.0 100.2 1.2 99.3 3.0 100.5 2.1
50.0 100.1 3.0 99.4 3.2 99.1 1.5
Overall mean recovery
(%) and CV (%)
100.0 1.9 99.6 1.9 100.2 1.8
a n = 6
Table 3. Results of precision of the chromatographic method
Theoretical cefotaxime
concentration (lg mL-1)
Mean experimental
concentration (lg mL-1)
CV (%)
Repeatability (intra-assay precision)a
0.20 0.199 1.0
0.39 0.388 0.7
0.78 0.788 1.5
1.56 1.564 2.3
3.13 3.135 1.9
6.25 6.247 1.8
12.5 12.473 1.2
25.0 25.006 2.4
50.0 49.965 2.1
Intermediate precisiona
0.20 0.199 1.7
0.39 0.390 1.8
0.78 0.782 1.8
1.56 1.559 1.2
3.13 3.133 0.7
6.25 6.249 1.5
12.5 12.488 2.4
25.0 24.999 2.5
50.0 49.969 1.0
a n = 6
Original Chromatographia 2010, 71, March (No. 5/6) 377
Precision
Table 3 summarizes precision of the
chromatographic method. Tables 4 and
5 summarize precision of the total ana-
lytical method, both intra-day and
intermediate precision, respectively. Ob-
tained CV values varied from 0.5 to 1.9
for the chromatographic method and
1.0–1.8 for intra-assay precision and
from 0.9 to 1.6 for intermediate precision
for the total analytical method, indicat-
ing that the used LC methodology
showed acceptable precision, in agree-
ment with the criteria proposed by
Table 4. Intra-assay precision of the entire analytical method for quantitation of cefotaxime from nanoparticle formulations prepared with
different Eudragit types
Theoretical cefotaxime
concentration (lg mL-1)
Eudragit L100 nanoparticlesa Eudragit L100-55 nanoparticlesa Eudragit S100 nanoparticlesa
Mean experimental
concentration (lg mL-1)
CV (%) Mean experimental
concentration (lg mL-1)
CV (%) Mean experimental
concentration (lg mL-1)
CV (%)
0.20 0.198 2.7 0.201 1.4 0.199 1.0
0.39 0.393 1.9 0.389 1.4 0.385 1.6
0.78 0.782 1.8 0.772 1.4 0.784 1.7
1.56 1.553 1.2 1.563 0.9 1.558 2.2
3.13 3.125 2.5 3.134 0.2 3.129 2.4
6.25 6.254 2.8 6.244 0.1 6.249 1.8
12.5 12.493 1.0 12.498 1.0 12.503 1.4
25.0 24.996 0.7 25.003 0.8 24.999 1.7
50.0 50.005 1.5 49.997 1.5 50.002 0.9
CV average (%) 1.8 1.0 1.6
a n = 6
Table 5. Intermediate precision of the entire analytical method for quantitation of cefotaxime from nanoparticle formulations prepared with
different Eudragit types
Theoretical cefotaxime
concentration (lg mL-1)
Eudragit L100 nanoparticlesa Eudragit L100-55 nanoparticlesa Eudragit S100 nanoparticlesa
Mean experimental
concentration (lg mL-1)
CV (%) Mean experimental
concentration (lg mL-1)
CV (%) Mean experimental
concentration (lg mL-1)
CV (%)
0.20 0.198 1.6 0.201 1.1 0.193 2.4
0.39 0.389 1.6 0.392 1.7 0.391 0.5
0.78 0.788 1.0 0.782 1.8 0.786 0.8
1.56 1.568 0.2 1.554 2.4 1.563 0.7
3.13 3.119 1.6 3.128 2.5 3.129 1.0
6.25 6.244 0.1 6.234 2.6 6.239 1.6
12.5 12.399 0.6 12.293 0.5 12.463 1.7
25.0 25.018 0.9 24.899 0.8 25.099 2.2
50.0 50.030 0.8 49.975 0.7 50.045 1.6
CV average (%) 0.9 1.6 1.4
a n = 6
Table 6. Results of recovery and CV for cefotaxime from standard solutions (125 lg mL-1) of different pH
Time (h) pH = 1.0a pH = 4.0a pH = 4.3a pH = 4.6a pH = 5.0a pH = 7.0a
Mean
recovery
(%)
CV
(%)
Mean
Recovery
(%)
CV
(%)
Mean
Recovery
(%)
CV
(%)
Mean
Recovery
(%)
CV
(%)
Mean
Recovery
(%)
CV
(%)
Mean
Recovery
(%)
CV
(%)
0.5 97.1 1.7 100.2 0.5 100.6 0.6 101.2 1.6 99.8 0.4 99.5 0.7
1 94.5 2.4 99.6 0.7 99.6 0.7 100.5 1.5 99.4 0.5 99.0 0.8
2 86.7 1.5 99.6 1.8 99.6 0.8 99.9 1.1 98.8 1.0 99.1 1.0
4 75.0 0.6 98.3 0.9 98.3 1.4 98.4 0.9 97.8 0.5 96.8 1.2
6 61.7 2.2 96.7 1.9 96.7 1.7 97.1 0.8 96.8 0.7 97.0 0.9
8 41.6 2.1 96.3 2.2 96.3 1.5 96.8 1.1 96.4 0.6 96.9 1.3
24 – 95.9 2.4 95.9 2.1 95.2 2.0 95.8 0.5 96.3 1.5
a n = 4
378 Chromatographia 2010, 71, March (No. 5/6) Original
Shabir [34], for which the mean CV
value should be lower than 2%.
Detection Limit and
Quantitation Limit
For the calculation of DL and QL the
calibration equations for cefotaxime so-
dium were generated by using the mean
values of the six independent calibration
curves. The obtained DL and QL values
were 0.045 and 0.135 lg mL-1, respec-
tively (i.e., the method is sensitive en-
ough to detect 0.045 lg mL-1 and
quantitate 0.135 lg mL-1 of cefotaxime
sodium in the studied conditions).
Robustness
Tables 6 and 7 summarize the robustness
results, expressed as percent recovery
and CV. As expected, for cefotaxime
solutions prepared either at pH 1.0 or on
USP 29 simulated gastric fluid, low
recovery values (&40%) were obtained
at the end of 8 h of incubation. Fabre
et al. [35] also reported a marked de-
crease of the cefotaxime concentration at
pH 1.6 with a 40% recovery after 8 h,
due to the hydrolysis of the drug.
Moreover, high CV values were ob-
served, revealing a low degree of repro-
ducibility of the results obtained in
referred conditions.
For standard solutions prepared ei-
ther at pH 4; 4.3; 4.6; 5 and 7, during 24 h
of incubation, or on simulated intestinal
fluid (during 8 h), high recovery and low
CV values were obtained. Cefotaxime
sodium standard solutions in the pH
range 4–7 showed recovery values be-
tween 95.2 and 96.3% (CV = 0.5–2.4%)
at the end of 24 h.
On simulated intestinal medium at the
endof 8 h, 90%of recovery (CV = 2.0%)
were obtained. These results indicate that,
for the pH range 4–7, the analytical pro-
cedure is robust with respect to sample
pH. This pH range comprises the pH
values at which cefotaxime is exposed
during the production of nanoparticles
and release studies in USP 29 simulated
intestinal fluid (pH 6.8 ± 0.1). Therefore,
the analytical procedure allows its use for
cefotaxime sodium quantitation either in
nanoparticle dispersions or in the release
studies from the nanoparticulate systems.
Interestingly, cefotaxime recovery in
simulated intestinal medium (90.0%) was
lower than that observed for the pH 7
solution (96.3%).This loss of drugmaybe
attributed to cefotaxime metabolism by
pancreatin present in simulated intestinal
fluid, as previously described for vanco-
mycin by Claudius and Neau [36].
The system suitability test was also
carried out to evaluate the reproducibil-
ity of the system for the analysis to be
performed, using six replicate injections
of a cefotaxime sodium standard solu-
tion (50 lg mL-1) prepared in a 0.04 M
NaH2PO42H2O buffer solution (pH
5.5). The results given in Table 8 show
that the evaluated parameters are within
the suitable range, as proposed by Dal-
mora et al. [37].
Application of the LC Method
for the Quantitation
of Cefotaxime Sodium
in Nanoparticles
The analytical method was shown to be
effective, fast and meeting all criteria for
method validation and was applied to
the quantitation of cefotaxime sodium
which was incorporated for the first time
in Eudragit pH-sensitive nanoparticles.
Figure 3a–c show representative
chromatograms of nanoparticles con-
taining cefotaxime sodium prepared with
different types of Eudragit (L100, L100-
50 and S100). None of the chromato-
grams showed any interfering peaks.
Table 9 shows the physicochemical
characterization parameters of nano-
particles, such as the mean particle size,
polydispersity index, zeta potential and
drug entrapment. Nanoparticles pre-
sented a mean size of approximately
100 nm with a narrow size distribution
and negative zeta potential. However,
their negativity varied with the Eudragit
type used, being more marked for
S100 nanoparticles (-26.9 ± 1.7 mV)
and less marked for L100 nanoparticles
(-12.3 ± 0.5 mV). Drug entrapment
values were low in all cases, ranging
between 4.3 and 5.0%, and their differ-
ences were not statistically significant
(P > 0.05). Low entrapment efficiencies
of cefotaxime sodium in Eudragit nano-
particles prepared by the current method
are due to the high water solubility of the
drug which migrates towards the exter-
nal aqueous phase during the nanopar-
ticle formation. This phenomenon is
even more pronounced due to the small
size of the nanoparticles and hence their
large surface area, as they undergo drug
loss into the aqueous phase during
formation. A similar explanation was
Table 7. Results of recovery and CV for cefotaxime from standard solutions (125 lg mL-1)
prepared in USP 29 simulated gastric and intestinal fluids
Time (h) Simulated gastric fluida Simulated intestinal fluida
Mean recovery (%) CV (%) Mean recovery (%) CV (%)
0.5 96.13 1.0 100.13 0.9
1 93.25 1.1 99.43 1.2
2 85.83 1.4 98.58 1.6
4 70.55 2.2 94.75 1.4
6 55.53 2.4 91.43 2.1
8 36.73 3.2 90.00 2.0
a n = 4
Table 8. Results of the system suitability test
Parameter Cefotaxime sodiuma
Minimum Maximum CV (%) Status
Retention time (min) 6.309 6.399 0.55 Passed
Peak height (V) 137645 142199 1.25 Passed
a n = 4
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proposed by Govender et al. [29] for the
incorporation of a water soluble drug
(procaine hydrochloride) in nanoparti-
cles.
Conclusions
A simple isocratic reverse-phase LC
method was validated for the determi-
nation of cefotaxime sodium in different
Eudragit type nanoparticles, which was
entrapped for the first time in these
nanocarriers. The proposed method is
simple, sensitive, reproducible and re-
quires a small sample volume. Obtained
results showed that it is specific, linear,
accurate and precise within the estab-
lished range, according to ICH guide-
lines and USP 29.
Validated method was successfully
applied to the quantitation of cefotaxime
sodium content in nanoparticle formu-
lations, affording an important tool for
the quality control of finished products.
Eudragit based nanosystems are under
optimization in order to improve drug
entrapment and oral bioavailability
studies are currently being undertaken in
rats.
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